Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.

NUPR1 is a critical repressor of ferroptosis

Open access

Abstract

Ferroptosis is a type of iron-dependent regulated cell death, representing an emerging disease-modulatory mechanism. Transcription factors play multiple roles in ferroptosis, although the key regulator for ferroptosis in iron metabolism remains elusive. Using NanoString technology, we identify NUPR1, a stress-inducible transcription factor, as a driver of ferroptosis resistance. Mechanistically, NUPR1-mediated LCN2 expression blocks ferroptotic cell death through diminishing iron accumulation and subsequent oxidative damage. Consequently, LCN2 depletion mimics NUPR1 deficiency with respect to ferroptosis induction, whereas transfection-enforced re-expression of LCN2 restores resistance to ferroptosis in NUPR1-deficient cells. Pharmacological or genetic blockade of the NUPR1-LCN2 pathway (using NUPR1 shRNA, LCN2 shRNA, pancreas-specific Lcn2 conditional knockout mice , or the small molecule ZZW-115) increases the activity of the ferroptosis inducer erastin and worsens pancreatitis, in suitable mouse models. These findings suggest a link between NUPR1-regulated iron metabolism and ferroptosis susceptibility.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-021-20904-2

Cites

76 of 76 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 NUPR1 acts as a repressor of ferroptosis. a A NanoString technology-based screening of differentially expressed tumor-associated genes in PANC1 and BxPC3 cells following treatment with erastin (10 µM) for 24 h. b Top 5 upregulated genes. c, d Nupr1+/+ and Nupr1−/− mPDAC cells were treated with erastin or RSL3 in the absence or presence of ferrostatin-1 (1 µM), liproxstatin-1 (1 µM), Z-VAD-FMK (10 µM), or necrosulfonamide (1 μM) for 24 h, and then cell viability (c) and lipid ROS (d) was measured (n = 3 well/group, two-way ANOVA with Tukey’s multiple comparisons test on all pairwise combinations). e qPCR analysis of NUPR1 expression in indicated mPDAC cells (n = 3 well/group, one-way ANOVA with Tukey’s multiple comparisons test on all pairwise combinations). f Cell viability of indicated mPDAC cells following treatment with erastin or RSL3 for 24 h (n = 3 well/group, two-way ANOVA with Tukey’s multiple comparisons test on all pairwise combinations). Data in d–f are presented as mean ± SD. The results in c–f are representative of those from 2 to 3 independent experiments with three technical replicates each. The results in a are representative of those from one independent experiment with three technical replicates each.
Fig. 1 NUPR1 acts as a repressor of ferroptosis. a A NanoString technology-based screening of differentially expressed tumor-associated genes in PANC1 and BxPC3 cells following treatment with erastin (10 µM) for 24 h. b Top 5 upregulated genes. c, d Nupr1+/+ and Nupr1−/− mPDAC cells were treated with erastin or RSL3 in the absence or presence of ferrostatin-1 (1 µM), liproxstatin-1 (1 µM), Z-VAD-FMK (10 µM), or necrosulfonamide (1 μM) for 24 h, and then cell viability (c) and lipid ROS (d) was measured (n = 3 well/group, two-way ANOVA with Tukey’s multiple comparisons test on all pairwise combinations). e qPCR analysis of NUPR1 expression in indicated mPDAC cells (n = 3 well/group, one-way ANOVA with Tukey’s multiple comparisons test on all pairwise combinations). f Cell viability of indicated mPDAC cells following treatment with erastin or RSL3 for 24 h (n = 3 well/group, two-way ANOVA with Tukey’s multiple comparisons test on all pairwise combinations). Data in d–f are presented as mean ± SD. The results in c–f are representative of those from 2 to 3 independent experiments with three technical replicates each. The results in a are representative of those from one independent experiment with three technical replicates each.CC BY · PubMed Central
Fig. 2 NUPR1 inhibits iron-dependent oxidative damage in ferroptosis. a Fe2+ levels in indicated mPDAC cells following treatment with erastin or RSL3 for 24 h (n = 3 well/group, two-way ANOVA with Tukey’s multiple comparisons test on all pairwise combinations). b–e Indicated mPDAC cells were treated with erastin (10 µM) or RSL3 (1 µM) in the absence or presence of DFO (100 µM) or NAC (1 mM) for 24 h, and then intracellular MDA (b), intracellular 8-OHdG (c), extracellular HMGB1 (d), and cell viability (e) were assayed (n = 3 well/group, two-way ANOVA with Tukey’s multiple comparisons test on all pairwise combinations). f qPCR analysis of Steap3 mRNA in indicated mPDAC cells (n = 3 well/group, two-way ANOVA with Tukey’s multiple comparisons test on all pairwise combinations). g, h Indicated mPDAC cells were treated with erastin (10 µM) or RSL3 (1 µM) or vehicle (0.01% dimethyl sulfoxide) for 24 h, and then extracellular HMGB1 (g) and cell viability (h) were determined (n = 3 well/group, two-way ANOVA with Tukey’s multiple comparisons test on all pairwise combinations). Data in a–h are presented as mean ± SD. The results in a–h are representative of those from 2 to 3 independent experiments with three technical replicates each.
Fig. 2 NUPR1 inhibits iron-dependent oxidative damage in ferroptosis. a Fe2+ levels in indicated mPDAC cells following treatment with erastin or RSL3 for 24 h (n = 3 well/group, two-way ANOVA with Tukey’s multiple comparisons test on all pairwise combinations). b–e Indicated mPDAC cells were treated with erastin (10 µM) or RSL3 (1 µM) in the absence or presence of DFO (100 µM) or NAC (1 mM) for 24 h, and then intracellular MDA (b), intracellular 8-OHdG (c), extracellular HMGB1 (d), and cell viability (e) were assayed (n = 3 well/group, two-way ANOVA with Tukey’s multiple comparisons test on all pairwise combinations). f qPCR analysis of Steap3 mRNA in indicated mPDAC cells (n = 3 well/group, two-way ANOVA with Tukey’s multiple comparisons test on all pairwise combinations). g, h Indicated mPDAC cells were treated with erastin (10 µM) or RSL3 (1 µM) or vehicle (0.01% dimethyl sulfoxide) for 24 h, and then extracellular HMGB1 (g) and cell viability (h) were determined (n = 3 well/group, two-way ANOVA with Tukey’s multiple comparisons test on all pairwise combinations). Data in a–h are presented as mean ± SD. The results in a–h are representative of those from 2 to 3 independent experiments with three technical replicates each.CC BY · PubMed Central
Fig. 3 LCN2 acts as an effector gene of NUPR1 in blocking ferroptosis. a Heatmap of relative mRNA levels of iron metabolism-associated genes in Nupr1+/+ and Nupr1−/− mPDAC cells following treatment with erastin (10 µM) or RSL3 (1 µM) for 24 h. b, c Analysis of LCN2 protein expression and Lcn2 promoter activity in Nupr1+/+ and Nupr1−/− mPDAC cells following treatment with erastin (10 µM) or RSL3 (1 µM) for 24 h (n = 3 well/group, one-tailed t test). d Binding of NUPR1 to Lcn2 promoter was analyzed using ChIP-qPCR in indicated mPDAC cells following treatment with erastin (10 µM) or RSL3 (1 µM) for 24 h (n = 3 well/group, one-tailed t test). e qPCR analysis of Lcn2 mRNA in indicated mPDAC cells following treatment with erastin (10 µM) or RSL3 (1 µM) for 24 h (n = 3 well/group, one-tailed t test). f Fe2+ levels in indicated mPDAC cells following treatment with erastin or RSL3 for 24 h (n = 3 well/group, two-way ANOVA with Tukey’s multiple comparisons test on all pairwise combinations). g–j Indicated mPDAC cells were treated with erastin (10 µM) or RSL3 (1 µM) in the absence or presence of DFO (100 µM) or liproxstatin-1 (1 µM) for 24 h, and then intracellular MDA (g), intracellular 8-OHdG (h), extracellular HMGB1 (i), and cell viability (j) were quantified (n = 3 well/group, two-way ANOVA with Tukey’s multiple comparisons test on all pairwise combinations). Data in b–j are presented as mean ± SD. The results in a–j are representative of those from 2 to 3 independent experiments with three technical replicates each.
Fig. 3 LCN2 acts as an effector gene of NUPR1 in blocking ferroptosis. a Heatmap of relative mRNA levels of iron metabolism-associated genes in Nupr1+/+ and Nupr1−/− mPDAC cells following treatment with erastin (10 µM) or RSL3 (1 µM) for 24 h. b, c Analysis of LCN2 protein expression and Lcn2 promoter activity in Nupr1+/+ and Nupr1−/− mPDAC cells following treatment with erastin (10 µM) or RSL3 (1 µM) for 24 h (n = 3 well/group, one-tailed t test). d Binding of NUPR1 to Lcn2 promoter was analyzed using ChIP-qPCR in indicated mPDAC cells following treatment with erastin (10 µM) or RSL3 (1 µM) for 24 h (n = 3 well/group, one-tailed t test). e qPCR analysis of Lcn2 mRNA in indicated mPDAC cells following treatment with erastin (10 µM) or RSL3 (1 µM) for 24 h (n = 3 well/group, one-tailed t test). f Fe2+ levels in indicated mPDAC cells following treatment with erastin or RSL3 for 24 h (n = 3 well/group, two-way ANOVA with Tukey’s multiple comparisons test on all pairwise combinations). g–j Indicated mPDAC cells were treated with erastin (10 µM) or RSL3 (1 µM) in the absence or presence of DFO (100 µM) or liproxstatin-1 (1 µM) for 24 h, and then intracellular MDA (g), intracellular 8-OHdG (h), extracellular HMGB1 (i), and cell viability (j) were quantified (n = 3 well/group, two-way ANOVA with Tukey’s multiple comparisons test on all pairwise combinations). Data in b–j are presented as mean ± SD. The results in a–j are representative of those from 2 to 3 independent experiments with three technical replicates each.CC BY · PubMed Central
Fig. 4 Re-expression of LCN2 rescues ferroptosis resistance in Nupr1-deficient cells. a qPCR analysis of Lcn2 mRNA in indicated mPDAC cells following treatment with erastin (10 µM) or RSL3 (1 µM) for 24 h (n = 3 well/group, two-way ANOVA with Tukey’s multiple comparisons test on all pairwise combinations). b Cell viability in indicated mPDAC cells following treatment with erastin or RSL3 for 24 h (n = 3 well/group, two-way ANOVA with Tukey’s multiple comparisons test on all pairwise combinations). c–f Indicated mPDAC cells were treated with erastin (10 µM) or RSL3 (1 µM) for 24 h, and then intracellular Fe2+ (c), intracellular MDA (d), intracellular 8-OHdG (e), and extracellular HMGB1 were assayed (n = 3 well/group, two-way ANOVA with Tukey’s multiple comparisons test on all pairwise combinations). Data in a–f are presented as mean ± SD. The results in a–f are representative of those from 2 to 3 independent experiments with three technical replicates each.
Fig. 4 Re-expression of LCN2 rescues ferroptosis resistance in Nupr1-deficient cells. a qPCR analysis of Lcn2 mRNA in indicated mPDAC cells following treatment with erastin (10 µM) or RSL3 (1 µM) for 24 h (n = 3 well/group, two-way ANOVA with Tukey’s multiple comparisons test on all pairwise combinations). b Cell viability in indicated mPDAC cells following treatment with erastin or RSL3 for 24 h (n = 3 well/group, two-way ANOVA with Tukey’s multiple comparisons test on all pairwise combinations). c–f Indicated mPDAC cells were treated with erastin (10 µM) or RSL3 (1 µM) for 24 h, and then intracellular Fe2+ (c), intracellular MDA (d), intracellular 8-OHdG (e), and extracellular HMGB1 were assayed (n = 3 well/group, two-way ANOVA with Tukey’s multiple comparisons test on all pairwise combinations). Data in a–f are presented as mean ± SD. The results in a–f are representative of those from 2 to 3 independent experiments with three technical replicates each.CC BY · PubMed Central
Fig. 5 The NUPR1–LCN2 pathway limits ferroptotic cancer cell death in vivo. a Athymic nude mice were injected subcutaneously with indicated PDHA1-knockdown (NUPR1KD) or LCN2-knockdown (LCN2KD) PANC1 cells for 7 days and then treated with IKE (40 mg/kg, i.p., once every other day) in the absence or presence of liproxstatin-1 (10 mg/kg, i.p., once every other day) at day 7 for 2 weeks. Tumor volumes were calculated weekly (n = 5 mice/group; two way ANOVA with Tukey’s multiple comparisons test on all pairwise combinations). b–e In parallel, the levels of Fe2+ (b), MDA (c), or PTGS2 mRNA (d) in isolated tumors and serum HMGB1 (e) at day 14 after treatment were assayed (n = 5 mice/group; one-way ANOVA with Tukey’s multiple comparisons test on all pairwise combinations). f Athymic nude mice were injected subcutaneously with PANC1 or MIAPaCa2 cells for 7 days and then treated with IKE (40 mg/kg, i.p., once every other day) in the absence or presence of ZZW-115 (5 mg/kg, i.p., once every other day) or liproxstatin-1 (10 mg/kg, i.p., once every other day) at day 7 for 2 weeks. Tumor volumes were calculated weekly (n = 5 mice/group; two-way ANOVA with Tukey’s multiple comparisons test on all pairwise combinations). g Indicated mPDAC cells were treated with erastin (10 µM) or RSL3 (1 µM) in the absence or presence ZZW-115 (2 µM) for 24 h and then cell death was assayed (n = 3 well/group, two-way ANOVA with Tukey’s multiple comparisons test on all pairwise combinations). ns: not significant. Data in a–e and g are presented as mean ± SD. The results in a–g are representative of those from 2 to 3 independent experiments.
Fig. 5 The NUPR1–LCN2 pathway limits ferroptotic cancer cell death in vivo. a Athymic nude mice were injected subcutaneously with indicated PDHA1-knockdown (NUPR1KD) or LCN2-knockdown (LCN2KD) PANC1 cells for 7 days and then treated with IKE (40 mg/kg, i.p., once every other day) in the absence or presence of liproxstatin-1 (10 mg/kg, i.p., once every other day) at day 7 for 2 weeks. Tumor volumes were calculated weekly (n = 5 mice/group; two way ANOVA with Tukey’s multiple comparisons test on all pairwise combinations). b–e In parallel, the levels of Fe2+ (b), MDA (c), or PTGS2 mRNA (d) in isolated tumors and serum HMGB1 (e) at day 14 after treatment were assayed (n = 5 mice/group; one-way ANOVA with Tukey’s multiple comparisons test on all pairwise combinations). f Athymic nude mice were injected subcutaneously with PANC1 or MIAPaCa2 cells for 7 days and then treated with IKE (40 mg/kg, i.p., once every other day) in the absence or presence of ZZW-115 (5 mg/kg, i.p., once every other day) or liproxstatin-1 (10 mg/kg, i.p., once every other day) at day 7 for 2 weeks. Tumor volumes were calculated weekly (n = 5 mice/group; two-way ANOVA with Tukey’s multiple comparisons test on all pairwise combinations). g Indicated mPDAC cells were treated with erastin (10 µM) or RSL3 (1 µM) in the absence or presence ZZW-115 (2 µM) for 24 h and then cell death was assayed (n = 3 well/group, two-way ANOVA with Tukey’s multiple comparisons test on all pairwise combinations). ns: not significant. Data in a–e and g are presented as mean ± SD. The results in a–g are representative of those from 2 to 3 independent experiments.CC BY · PubMed Central
Fig. 6 LCN2 prevents pancreatitis through the inhibition of ferroptosis. a Western blot analysis of LCN2 expression in the pancreas and liver in Lcn2flox/flox and pancreas-specific conditional Lcn2 knockout mice (Lcn2Pan−/−). b Animal survival in Lcn2flox/flox and Lcn2Pan−/− mice in response to l-arginine-induced acute severe pancreatitis in the absence or presence of liproxstatin-1 or DFO (n = 10 mice/group; one-sided Log-rank [Mantel–Cox] test). c–h In parallel, hematoxylin and eosin-stained pancreatic sections (c), serum amylase (d), pancreatic MPO (e), serum HMGB1 (f), pancreatic MDA (g), and mRNA expression of Ptgs2 in the pancreas (h) were assayed at the indicated time points (n = 3 mice/group; two-way ANOVA with Tukey’s multiple comparisons test on all pairwise combinations). Bar = 50 μm. ns: not significant. Data in d–h are presented as mean ± SD. The results in b–h are representative of those from two independent experiments. The results in (a) are from an independent experiment.
Fig. 6 LCN2 prevents pancreatitis through the inhibition of ferroptosis. a Western blot analysis of LCN2 expression in the pancreas and liver in Lcn2flox/flox and pancreas-specific conditional Lcn2 knockout mice (Lcn2Pan−/−). b Animal survival in Lcn2flox/flox and Lcn2Pan−/− mice in response to l-arginine-induced acute severe pancreatitis in the absence or presence of liproxstatin-1 or DFO (n = 10 mice/group; one-sided Log-rank [Mantel–Cox] test). c–h In parallel, hematoxylin and eosin-stained pancreatic sections (c), serum amylase (d), pancreatic MPO (e), serum HMGB1 (f), pancreatic MDA (g), and mRNA expression of Ptgs2 in the pancreas (h) were assayed at the indicated time points (n = 3 mice/group; two-way ANOVA with Tukey’s multiple comparisons test on all pairwise combinations). Bar = 50 μm. ns: not significant. Data in d–h are presented as mean ± SD. The results in b–h are representative of those from two independent experiments. The results in (a) are from an independent experiment.CC BY · PubMed Central
Fig. 7 Prognostic significance of the NUPR1–LCN2 pathway in human PDAC. a Upregulation of LCN2 (but not NUPR1) gene expression within the tumor from PDAC patients compared to normal controls using datasets from the Cancer Genome Atlas (TCGA) (one-tailed t test). The data are presented as box-and-whisker plots. Boxes represent the median and the 25th and 75th percentiles. ns: not significant. n is number of cases. b Kaplan–Meier survival analysis of NUPR1 and LCN2 gene expression in PDAC patients using TCGA datasets (one-sided Log-rank [Mantel–Cox] test). n is number of cases. c Schematic representation of the role of NUPR1 in the regulation of ferroptosis in human PDAC cells.
Fig. 7 Prognostic significance of the NUPR1–LCN2 pathway in human PDAC. a Upregulation of LCN2 (but not NUPR1) gene expression within the tumor from PDAC patients compared to normal controls using datasets from the Cancer Genome Atlas (TCGA) (one-tailed t test). The data are presented as box-and-whisker plots. Boxes represent the median and the 25th and 75th percentiles. ns: not significant. n is number of cases. b Kaplan–Meier survival analysis of NUPR1 and LCN2 gene expression in PDAC patients using TCGA datasets (one-sided Log-rank [Mantel–Cox] test). n is number of cases. c Schematic representation of the role of NUPR1 in the regulation of ferroptosis in human PDAC cells.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 76 references

Cited by

See all 290

Metadata

Authors
Liu, J., Song, X., Kuang, F., Zhang, Q., Xie, Y., Kang, R., Kroemer, G., & Tang, D.
Affiliations
  • Third Affiliated Hospital of Guangzhou Medical University (CN)
  • The University of Texas Southwestern Medical Center (US)
  • University of Pittsburgh (US)
  • Central South University (CN)
  • Karolinska University Hospital (SE)
Corresponding author
  • Kroemer, Guido
  • Tang, Daolin
Venue
Nature Communications
Published
2021-01-28
Volume
12
Issue
1
Pages
647-647
ISSN
2041-1723 (ISSN-L)
OpenAlex
W3125788801
Cited by
290
References
76
Citations by year
2026: 40 · 2025: 58 · 2024: 70 · 2023: 53 · 2022: 49 · 2021: 20
FWCI
31.12
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, other-oa)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
  • Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
Keywords
NUPR1, ferroptosis, ferroptosis resistance, neutrophil gelatinase-associated lipocalin, iron metabolism, iron accumulation, oxidative damage, transcription factors, pancreatitis, erastin, conditional knockout mice
MeSH terms
RNAi Therapeutics, Lipocalin-2, Ferroptosis, Animals, DNA-Binding Proteins, Humans, Iron, Mice, Nude, Mice, Transgenic, Neoplasm Proteins, Pancreatic Neoplasms, Piperazines, Thiazines, Signal Transduction, Gene Expression Regulation, Neoplastic, Mice, Knockout, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: NUPR1 is a critical repressor of ferroptosis. https://app.cochat.ai/papers/10.1038/s41467-021-20904-2
The paper
Liu, J., Song, X., Kuang, F., Zhang, Q., Xie, Y., Kang, R., Kroemer, G., & Tang, D. (2021). NUPR1 is a critical repressor of ferroptosis. Nature Communications. https://doi.org/10.1038/s41467-021-20904-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.